Connect with us

Press Release

Macao Blusea Digital Asset Exchange—Exploring the Ocean of the Digital Economy

Published

on

The Macao International Brand Exchange is licensed by the Macao government. Besides being a market maker for tangible assets like traditional centralized exchanges, it has also founded Blusea Digital Asset Exchange, a next-generation decentralized platform where people trade NFTs, metaverse items, derivatives etc., digitalize real-world assets, as well as benefit from various DeFi services. 

In 2009, China approved the Hengqin Overall Development Plan to incorporate Hengqin into Zhuhai Special Economic Zone with a view to gradually building the island into a demonstration zone for the new collaborative relationship among Guangdong, Hong Kong and Macao under One Country Two Systems. Coincidentally, it was also in 2009 that Satoshi Nakamoto invented Bitcoin and opened the Pandora Box of the digital economy.

On the wings of China’s Reform and Opening-up, the Macau International Brand Exchange stumbled upon this Pandora Box and decided to seize the opportunity.

C:UsersADMINI~1AppDataLocalTempWeChat Filesbd58d6062cb78cd628425f9ad94f244.png

Macao Blusea Digital Asset Exchange

BluSea’s Core Business

As a next-generation metaverse exchange, BluSea is not only involved in NFT and DeFi, but also supports the digitalization of assets. Not restricting its business to digital artworks or game NFTs, BluSea understands the game-changing potential of real-world asset digitalization. Blusea’s introduction of DeFi is also expected to boost the value of users’ metaverse assets. 

图片 1

Digitalization of Real-world Assets

BluSea’s Technological Advantage and Security System

Both NFT and DeFi need to be supported by powerful technologies and a trustworthy security system. BluSea has adopted AI-powered formal verification to safeguard assets and smart contracts. BluSea boasts Nasdaq-level concurrency thanks to its AI-optimized network environment. AI quantitative transaction, smart financing as well as transaction route optimization will lower the barrier to trading assets in the metaverse.

When it comes to security, BluSea uses cutting-edge multi-level protection strategies for the front and back ends to safeguard the user terminal for asset safety.

BluSea’s Diverse Use Scenarios

BLUS is the only official token on BluSea. Besides paying transaction fees, granting voting power, minting NFTs and other conventional uses, BLUS also supports cross-border payment and free exchange into foreign currencies through Paypal thanks to One Country Two Systems.  

图片 5

Cross-border Payment

BluSea and OpenSea

In contrast to OpenSea’s sole focus on NFT trading, BluSea integrates NFT, DeFi and the AI-powered self-improving IPFS public chain—BLUS Chain.

BLUS Chain is a powerful next-generation public chain designed specifically for the metaverse. It uses IPFS for its basic data storage layer to provide distributed storage for metaverse assets and AI technologies to achieve high efficiency and security. Meanwhile, thanks to BluSea’s own cross-chain bridge Maelstrom, NFT assets can freely flow to and from mainstream public chains such as Ethereum, BSC, HECO, etc, which helps boost the liquidity of NFT and attract more users and investments to BluSea.

The integration of blockchain and semiconductor technologies will enable BluSea to build a platform for digital mirroring, which will allow users to bring their real-world assets into the virtual world and become the first people to witness the era of the metaverse.

图片 3

Digital Mirroring

A New Chapter for the Digital Economy

Into the era of the digital economy, countries around the world are competing for an early lead. Europe, Canada, Australia and other developed countries have all launched Bitcoin ETFs. El Salvador went one step ahead and made Bitcoin its fiat currency.

查看源图像

The Digital Economy

In the meanwhile, in the 2021 CIFTIS—Global Trade in Services Summit, Chinese president Xi Jinping said, “We will join hands with all parties, continue to open up and cooperate for mutual benefit and share opportunities in service trading for the recovery and sustained growth of the world economy. We will build a mature system of rules for the service industry, and start by testing international free trade agreement rules in Beijing and other cities, building pilot zones for digital trade. We will continue to support the development of SMEs, deepen the reform of the OTC market, establish the Beijing Stock Exchange and develop SMEs into the main force for innovation in the service sector.

The Greater Bay Area is China’s primary window to the global economy. In Outline Development Plan for the Guangdong-Hong Kong-Macao Greater Bay Area issued by the State Council in 2019, it was clearly stated that building a stock market with RMB-based settlement in Macao is being studied. Now China’s national cryptocurrency DCEP has been launched in several cities, and BluSea as a digital token platform will not only help SMEs to get on the fast track of digitalization but also play an exemplary role as a pioneer in digital trade.

With support from the state, BluSea Exchange as well as the Macau International Brand Exchange will continue to focus on developing the digital economy to empower the real economy. Together they will explore new business models, facilitate the development of new economies, help build China’s influence in the international financial sector. Eventually, the Greater Bay Area will welcome a new chapter of the international digital economy with Hengqin as its center.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders

Published

on

Dubai, United Arab Emirates, 13th Mar 2026 – ForexBrokers.Live is changing the way traders approach MetaTrader 4 (MT4) and MetaTrader 5 (MT5) platforms. The platform provides forex traders with essential tools, expert insights, and comprehensive guides to make informed decisions when choosing between these popular trading platforms.

MT4 has long been the go-to platform for forex traders, valued for its simplicity and reliability. Meanwhile, MT5 takes trading to the next level, offering additional features for more advanced traders, such as access to a wider range of financial instruments and enhanced charting capabilities. ForexBrokers.Live is committed to helping traders understand these platforms and how they can be used to maximize success in the forex market.

Empowering Traders with Knowledge

ForexBrokers.Live provides easy-to-understand guides that break down the complexities of both MT4 and MT5. The platform doesn’t just explain how to download and set up these platforms, it also offers expert reviews, broker comparisons, and practical tips on using advanced tools effectively. Whether you’re a beginner or an experienced trader, ForexBrokers.Live ensures you have the resources to choose the right broker and platform.

Choosing the Right Broker

Selecting the right broker is as important as choosing the right platform. ForexBrokers.Live makes this process easier by comparing brokers that support MT4 and MT5, highlighting their unique features, spreads, execution speeds, and customer support. This helps traders find the best-suited broker for their needs.

The platform goes beyond platform usage to offer in-depth broker reviews, ensuring traders are well-equipped to navigate the forex market confidently. ForexBrokers.Live also regularly updates its content, so users always have the latest information on brokers and platform features.

Looking Forward

ForexBrokers.Live continues to evolve to meet the growing needs of the trading community. The platform plans to expand its content with more detailed guides, updated reviews, and new features designed to keep traders informed and ready for the market’s challenges.

About ForexBrokers.Live

ForexBrokers.Live is a dedicated resource for forex traders, offering comprehensive guides, expert reviews, and broker comparisons for MetaTrader 4 (MT4) and MetaTrader 5 (MT5). With a focus on clarity and practicality, ForexBrokers.Live helps traders of all levels make informed decisions and choose the best platforms and brokers for their needs.

Media Contact

Organization: ForexBrokers.Live

Contact Person: Manish

Website: https://forexbrokers.live

Email: Send Email

City: Dubai

Country:United Arab Emirates

Release id:42570

The post ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC

Published

on

Export, PA, United States, 13th Mar 2026 – The upcoming episode of Now We Know! with Steve Guttenberg, airing March 14, 2026 at 1pm ET on CNBC will feature FS-Elliott, a company specializing in the design and manufacturing of high-performance centrifugal air and gas compressors.

The segment provides viewers with a behind-the-scenes look at the engineering and precision required to produce industrial equipment that supports manufacturing, energy production, and critical infrastructure worldwide. Through advanced technology and meticulous design, FS-Elliott’s compressors help power operations across a wide range of industries.

From reliability and efficiency to long-term performance, the episode highlights the role that specialized equipment plays in keeping industrial systems running smoothly.

By showcasing FS-Elliott’s work, Now We Know! sheds light on the often-unseen technologies that support modern industry. The series continues its mission to reveal the innovation and expertise behind the systems that drive everyday life.

About Now We Know!

Hosted by actor, author, and businessman, Steve Guttenberg, this unique platform inspires the next generation of knowledge seekers and viewers around the country. Each episode features up to four industry experts who provide their own unique perspective on the topic at hand via a 6-8–minute segment produced by our team, bringing a fresh look at interesting narratives, moderated by the one and only Steve Guttenberg. 

Learn more at NowWeKnowTV.com

About FS-Elliott Co., LLC

FS-Elliott is a global leader in the engineering and manufacturing of oil-free, centrifugal air and gas compressors, with operations in over 90 countries. For over 60 years, FS-Elliott has combined a commitment to quality with advanced technology, enabling our customers to increase productivity and lower system operating costs. For more information, visit www.fs-elliott.com.

For more details, contact:

Now We Know! with Steve Guttenberg

(877) 546-9995

feature@nowweknowtv.com

nowweknowtv.com

SOURCE Now We Know! with Steve Guttenberg

All images courtesy of Now We Know! with Steve Guttenberg

 

Media Contact

Organization: Now We Know!with Steve Guttenberg

Contact Person: Media Relations

Website: https://nowweknowtv.com/

Email: Send Email

Contact Number: +18775469995

City: Export

State: PA

Country:United States

Release id:42579

The post FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China

Published

on

SHENZHEN, CHINA China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.

The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.

More information about Desidustat Tablets and Renal Anaemia

As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.

There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.

Desidustat Tablets have been approved for marketing in India.

CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.

The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference

1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6

2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015

3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)

4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST